AU Patent

AU2024306538A1 — Combination therapy

Assigned to Zealand Pharma AS · Expires 2025-12-04 · 0y expired

What this patent protects

The present invention relates to use of an amylin analogue and a dual agonist of the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide- 1 receptor (GLP-1R) to regulate body weight and to treat or prevent obesity and related conditions.

USPTO Abstract

The present invention relates to use of an amylin analogue and a dual agonist of the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide- 1 receptor (GLP-1R) to regulate body weight and to treat or prevent obesity and related conditions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024306538A1
Jurisdiction
AU
Classification
—
Expires
2025-12-04
Drug substance claim
No
Drug product claim
No
Assignee
Zealand Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.